Literature DB >> 1637132

Mild senile dementia of the Alzheimer type. 4. Evaluation of intervention.

L Berg1, J P Miller, J Baty, E H Rubin, J C Morris, G Figiel.   

Abstract

The design of trials of interventions intended to slow or arrest the progression of senile dementia of the Alzheimer type must be based on analysis of the natural history of the disease. Using a random coefficients statistical model, we analyzed the natural history of senile dementia of the Alzheimer type in carefully defined subjects with mild disease (n = 68) for periods of up to 10 years. Subject performance was assessed longitudinally on batteries of clinical and psychometric measures. The characteristics of these measures were analyzed relevant to their utility as outcome measures for long-term trials in patients with senile dementia of the Alzheimer type. Estimates were made of sample sizes required to show arrest, and 50% or 25% slowing in the progression of mild disease. We suggest that a clinically relevant global measure, such as the Sum of Boxes of the Clinical Dementia Rating scale, and a performance-based clinical scale or psychometric measure would be appropriate in a 12- or 24-month trial enrolling subjects with mild senile dementia of the Alzheimer type.

Entities:  

Mesh:

Year:  1992        PMID: 1637132     DOI: 10.1002/ana.410310303

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  31 in total

Review 1.  Acetylcholinesterase inhibitors in Alzheimer's disease.

Authors:  B M McGleenon; K B Dynan; A P Passmore
Journal:  Br J Clin Pharmacol       Date:  1999-10       Impact factor: 4.335

2.  The experience of caregiving: differences between behavioral variant of frontotemporal dementia and Alzheimer disease.

Authors:  Cindy Wong; Jennifer Merrilees; Robin Ketelle; Cynthia Barton; Margaret Wallhagen; Bruce Miller
Journal:  Am J Geriatr Psychiatry       Date:  2012-08       Impact factor: 4.105

3.  Autoregulation of cerebral blood flow to changes in arterial pressure in mild Alzheimer's disease.

Authors:  Allyson R Zazulia; Tom O Videen; John C Morris; William J Powers
Journal:  J Cereb Blood Flow Metab       Date:  2010-08-25       Impact factor: 6.200

4.  Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type.

Authors:  Barbara J Snider; Anne M Fagan; Catherine Roe; Aarti R Shah; Elizabeth A Grant; Chengjie Xiong; John C Morris; David M Holtzman
Journal:  Arch Neurol       Date:  2009-05

5.  Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study.

Authors:  Stephanie Jb Vos; Chengjie Xiong; Pieter Jelle Visser; Mateusz S Jasielec; Jason Hassenstab; Elizabeth A Grant; Nigel J Cairns; John C Morris; David M Holtzman; Anne M Fagan
Journal:  Lancet Neurol       Date:  2013-09-04       Impact factor: 44.182

6.  Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease.

Authors:  Rawan Tarawneh; Gina D'Angelo; Elizabeth Macy; Chengjie Xiong; Deborah Carter; Nigel J Cairns; Anne M Fagan; Denise Head; Mark A Mintun; Jack H Ladenson; Jin-Moo Lee; John C Morris; David M Holtzman
Journal:  Ann Neurol       Date:  2011-08       Impact factor: 10.422

7.  Autobiographical memory task in assessing dementia.

Authors:  Denise Maue Dreyfus; Catherine M Roe; John C Morris
Journal:  Arch Neurol       Date:  2010-07

8.  Deaths attributable to Alzheimer's disease in the United States.

Authors:  D C Ewbank
Journal:  Am J Public Health       Date:  1999-01       Impact factor: 9.308

9.  A brief clinical tool to assess physical function: the mini-physical performance test.

Authors:  Consuelo H Wilkins; Catherine M Roe; John C Morris
Journal:  Arch Gerontol Geriatr       Date:  2009-03-12       Impact factor: 3.250

10.  Phenotypic Similarities Between Late-Onset Autosomal Dominant and Sporadic Alzheimer Disease: A Single-Family Case-Control Study.

Authors:  Gregory S Day; Erik S Musiek; Catherine M Roe; Joanne Norton; Alison M Goate; Carlos Cruchaga; Nigel J Cairns; John C Morris
Journal:  JAMA Neurol       Date:  2016-09-01       Impact factor: 18.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.